Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Protagonist Therapeutics, Inc. (PTGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
4Distinct source URLs
7High confidence
0.770Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Protagonist Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CONTRACT-MANUFACTURERS
CONTRACT-MANUFACTURERS
90%
We also rely on our contract manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials.
ld negatively impact our business. ● If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or…
Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we…
Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain not…
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PTGX graph: s and Other Commitments In the no…
ZLDPF
Zealand Pharma A/S
72%
s and Other Commitments In the normal course of business, we enter into agreements with contract service providers to assist in the performance of our research and development activities and clinical…
Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: The Company has earned a total of $ 387.5 million in non-refundable payments from JNJ under the JNJ License and Collab…
Reciprocal relationship from MLTX graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from MLTX g…
Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain not…
de whole with respect to a future bank failure, account holders’ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in t…
JANSSEN-BIOTECH-INC
JANSSEN-BIOTECH-INC
62%
ve date of the contract through December 31, 2024. The Company determined that the Takeda Collaboration Agreement met the definition of a collaborative arrangement under ASC Topic 808. Both parties…
TAKEDA-PHARMACEUTICALS-USA-INC
TAKEDA-PHARMACEUTICALS-USA-INC
62%
Item 1A, “ Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decisio…
Protagonist Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PTGX-DEBT
Debt stack $9.8M
90%
Market cache reports total debt of $9.8M.
PTGX-DEBT-11934
Warrants outstanding: 1500000
90%
xbrl warrant detail from xbrl 2026-03-31.
PTGX-DEBT-11935
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-12-31.
Protagonist Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Protagonist Therapeutics, Inc..
Protagonist Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
PTGX-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 325 tracked holders.
Protagonist Therapeutics, Inc. Extended Supply Chain Network
